ProMed Pharma continues formulation work on Cardiff University's EMBED 3.0
- Cardiff University
- Direct award
- 2 November 2026 to 31 December 2026
Cardiff University has asked ProMed Pharma, LLC to improve the formulations for EMBED 3.0, a project developing a way of delivering medication to patients.
The B&M Gates Foundation, which funds EMBED, reviewed the work with the research team. ProMed had carried out that earlier development, which was also awarded directly. To move on to EMBED 4.0 and human trials, the team must show it can vary further batches so medication enters patients more reliably. The foundation is paying for this extra work too.
The £187,587 contract was awarded directly in October 2026 and is due to end in December 2026.
Contract ends December 2026
- What
- Aseptic compounding, specials and contract pharmaceutical manufacturing
- Buyer
- Cardiff University
- Supplier
- ProMed Pharma, LLC
- Value
- £187,587
- How it was bought
- Direct award
- Dates and next
- Nov 2026 to Dec 2026